Anti-amyloid Antibody Therapies for Alzheimer’s Disease
Nuclear Medicine and Molecular Imaging · 2024-06 · 58 (4) · 227-236
DOI: 10.1007/s13139-024-00848-3 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Nuclear Medicine and Molecular Imaging, online erschienen am 20.02.2024. Verfasst von Kyung Won Park. Beteiligte Einrichtung: Department of Neurology, Dong-A University College of Medicine, 26 Daesingongwon-Ro, Seo-Gu, Busan, 49201 Korea. Die Arbeit wurde bisher 25-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Demenz
Abstract (Originalsprache)
Alzheimer's disease (AD) is the most common cause of dementia, which is characterized by a progressive neurodegenerative disorder that is extremely difficult to treat and severely reduces quality of life. Amyloid beta (Aβ) has been the primary target of experimental therapies owing to the neurotoxicity of Aβ and the brain Aβ load detected in humans by amyloid positron emission tomography (PET) imaging. Recently completed phase 2 and 3 trials of third-generation anti-amyloid immunotherapies indicated clinical efficacy in significantly reducing brain Aβ load and inhibiting the progression of cognitive decline. Anti-amyloid immunotherapies are the first effective disease-modifying therapies for AD, and aducanumab and lecanemab were recently approved through the US Food and Drug Administration's accelerated approval pathway. However, these therapies still exhibit insufficient clinical efficacy and are associated with amyloid-related imaging abnormalities. Further advances in the field of AD therapeutics are required to revolutionize clinical AD treatment, dementia care, and preventive cognitive healthcare.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Department of Neurology, Dong-A University College of Medicine, 26 Daesingongwon-Ro, Seo-Gu, Busan, 49201 Korea.
- Department of Translational Biomedical Sciences, Graduate School, Dong-A University, 26 Daesingongwon-Ro, Seo-Gu, Busan, 49201 Korea.
ORCID-Profile: Kyung Won Park
Zitieren
APA
Park, K. W. (2024). Anti-amyloid Antibody Therapies for Alzheimer’s Disease. Nuclear Medicine and Molecular Imaging, 58(4), 227-236. https://doi.org/10.1007/s13139-024-00848-3
Vancouver
Park KW. Anti-amyloid Antibody Therapies for Alzheimer’s Disease. Nuclear Medicine and Molecular Imaging. 2024;58(4):227-236. doi:10.1007/s13139-024-00848-3
BibTeX
@article{Park2024,
author = {Park, Kyung Won},
title = {Anti-amyloid Antibody Therapies for Alzheimer’s Disease},
journal = {Nuclear Medicine and Molecular Imaging},
year = {2024},
volume = {58},
number = {4},
pages = {227--236},
doi = {10.1007/s13139-024-00848-3}
}
EUVIMED